Bleehen N M, Wiltshire C R, Plowman P N, Watson J V, Gleave J R, Holmes A E, Lewin W S, Treip C S, Hawkins T D
Br J Cancer. 1981 Apr;43(4):436-42. doi: 10.1038/bjc.1981.64.
The results are reported of a small clinical trial carried out to assess the potential value of the hypoxic cell radiosensitizer misonidazole in the radiation treatment of Grade 3 and 4 supratentorial astrocytomas. A total of 55 patients were randomly allocated to one of 3 treatment groups. No significant differences were seen between the median survivals of patients in the 2 control radiation groups and that of the third group in which oral misonidazole at a dose of 3 g/m2 preceded each of 4 weekly radiation doses. Possible reasons why no improvement was seen are discussed in detail.
报告了一项小型临床试验的结果，该试验旨在评估乏氧细胞放射增敏剂米索硝唑在3级和4级幕上星形细胞瘤放射治疗中的潜在价值。总共55名患者被随机分配到3个治疗组之一。在两个对照放疗组患者的中位生存期与第三组（在每周4次放疗剂量的每次之前口服3 g/m²米索硝唑）患者的中位生存期之间未观察到显著差异。详细讨论了未见改善的可能原因。
